New Testosterone-Based Gel Livens Up Female Libido
MedHeadlines • Jul 25th, 2008
A woman’s waning desire for sexual interaction is often attributed to the
process but not every woman loses interest in the opposite sex once
menopause. Many postmenopausal women remain sexually active and happy
about it while others experience some very real physical issues that make
pleasant than it once. Others just don’t seem to miss it.
There’s hope for romance in the future, however, even when a medical
called hypoactive sexual desire disorder (HSDD) has been
diagnosed. A research
team based at the University of North Carolina (UNC),
Chapel Hill, have just
released the findings of a Phase II study involving a
testosterone-based gel that was
reported to improve sexual satisfaction by
more than 200% in women with
hypoactive sexual desire disorder. The gel, to
be marketed as LibiGel once final
testing is completed and the drug is
approved for sale, contains testosterone, the
sexual hormone most often
associated with men.
Women, too, require testosterone for sexual arousal but the female body’s
to produce the male hormone diminishes after menopause. To use the
restoring new gel, women simply apply it to the upper arm, where it
through the skin in a controlled dose all day long.
The research team evaluated the intimate lives of more than 2,200 30- to
old women to measure the potential benefits of the gel. About 26.7%
premenopausal women participating in the study reported low sex drives
than half, 52%, of postmenopausal women did so.
Within the study group, women who were surgically menopausal seemed to
the greatest difficulties, with 12.5% of them diagnosed with HSDD.
experienced natural menopause had HSDD about 1.2% more often then
premenopausal women. The medical condition, HSDD, is a more extreme lack of
desire that is characterized by enough anxiety to seriously test
While using LibiGel, the surgically menopausal women reported 238% more
satisfying sexual encounters than before using the gel. The very high rate
of the testosterone-laced gel makes it highly desirable in the
treatment of sexual
dysfunction in postmenopausal women. The gel is still
undergoing testing at this
time, however, with current study participants
who are all experiencing menopause
and have HSDD, too.
The July 14, 2008, issue of the Archives of Internal Medicine
carries the details
of the UNC study. The study was a
joint effort between UNC researchers and
BioSante Pharmaceuticals, Inc., the
gel’s manufacturer. BioSante is headquartered
in Lincolnshire, Illinois.
Source: BioSante Pharmaceuticals